// App-Quantinova.ai

9046 : Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma.

Researchers

Presenter

  • Timothy Dudley Clay

Principal Investigators

  • Margarita Majem

  • Enriqueta Felip

  • Bernard Doger

  • Enric Carcereny Costa

  • Martin Forster

  • Matthew Krebs

  • Julio Antonio Peguero

  • Christian Mueller

  • Frederic Triebel

Medical Centers

  • St John of God Hospital, Perth, Australia

  • Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

  • Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain

  • START Madrid. Fundacion Jimenez Diaz, Madrid, Spain

  • Institut Catala d'Oncologia, Hospital Universitario German Trias i Pujol, Badalona, Spain

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

  • Oncology Consultants PA, Houston, TX

  • Clinical Development, Immutep, Berlin, Germany

  • Research & Development, Immutep, Paris, France

Locations

  • Australia

  • Spain

  • United Kingdom

  • Germany

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • EDP 202

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • II

Study Id's

  • NCT03625323

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved